Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06086756 · ClinicalTrials.gov registry record · NA
Virtual Reality Intervention for Speech Anxiety
A NA study of Public Speaking and Speech Anxiety, sponsored by Boston University Charles River Campus.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT06086756: Completed NA study of Public Speaking and Speech Anxiety, sponsored by Boston University Charles River Campus.
NCT06086756 is a NA study of Public Speaking and Speech Anxiety that has completed, run by Boston University Charles River Campus. The registered enrollment target is 48 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06086756, a NA study of Public Speaking and Speech Anxiety, has completed, sponsored by Boston University Charles River Campus.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Exposure-based cognitive behavior therapy is an efficacious treatment for speech anxiety and has been delivered effectively in a virtual reality (VR) environment. The present study is designed to evaluate whether mood state moderates outcome to a brief VR exposure intervention.
Primary Outcome
Assessed using the Personal Report of Communication Apprehension, Public Speaking Subscale (PRCA-PS)
Conditions Studied
Interventions
- BEHAVIORAL Exposure intervention plus positive mood induction
- BEHAVIORAL Exposure intervention plus negative mood induction
Study Locations (1)
Massachusetts
- Center for Anxiety and Related Disorders - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2023-12-05 |
| Phase | NA |
What the finished NCT06086756 record still lists
NCT06086756 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Public Speaking appearing as the primary indexed condition, and to 2 interventions - of which Exposure intervention plus positive mood induction is the first listed.
NCT06086756 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06086756 about?
NCT06086756 is a clinical study titled "Virtual Reality Intervention for Speech Anxiety". Exposure-based cognitive behavior therapy is an efficacious treatment for speech anxiety and has been delivered effectively in a virtual reality (VR) environment. The present study is designed to evaluate whether mood state moderates outcome to a brief VR exposure intervention.
What is the current status of trial NCT06086756?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2023-11-01. Estimated completion is 2023-12-05.
What conditions does trial NCT06086756 study?
This clinical trial studies the following conditions: Public Speaking, Speech Anxiety.
What interventions are being tested in trial NCT06086756?
The interventions under investigation include: Exposure intervention plus positive mood induction (BEHAVIORAL), Exposure intervention plus negative mood induction (BEHAVIORAL).
Who is sponsoring clinical trial NCT06086756?
This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06086756 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06086756's enrollment target sits among peer trials
48 1381st of 2000 higher than 601 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI